Publication date: Jul 12, 2024
Since lung transplant recipients (LTRs) exhibit low immunogenicity after two doses of SARS-CoV-2 mRNA vaccines, optimal vaccine strategies for SARS-CoV-2 are required in LTRs. This study aimed to investigate the efficacy and safety of the third and fourth doses of the SARS-CoV-2 mRNA vaccines in LTRs. We conducted a single-center study of 73 LTRs and 23 healthy controls (HCs). Participants received two-to-four doses of SARS-CoV-2 mRNA vaccines. The LTRs were divided into three groups based on the number of vaccine dose. IgG titers against SARS-CoV-2 spike protein were measured, and adverse events were assessed. Factors associated with humoral response were analyzed using univariate and multivariate analyses. The Dose 4 group (n = 27) had a higher humoral response rate (P = 0. 018) and higher levels of anti-SARS-CoV-2 IgG antibody (P = 0. 04) than the Dose 2 group (n = 14). The Dose 3 group (n = 32) had lower humoral response rates (P = 0. 005) and levels of anti-SARS-CoV-2 IgG antibody (P = 0. 0005) than the HCs (n = 23) even after the same dose. Systemic adverse events were milder in the LTRs than in the HCs (P
| Concepts | Keywords |
|---|---|
| Fourth | Adverse events |
| Healthy | COVID-19 |
| Lung | Immunogenicity |
| Mrna | Lung transplantation |
| Vaccine | mRNA vaccine |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | VO | dose |
| disease | VO | vaccine |
| disease | VO | vaccine dose |
| disease | MESH | COVID-19 |